Ironwood Pharmaceuticals, Inc. Class A
(NASDAQ : IRWD)

( )
IRWD After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.15%16.5714.1%$326.42m
SHPGShire PLC Sponsored ADR
-1.28%147.860.4%$206.46m
PRGOPerrigo Co. Plc
-0.13%86.596.6%$131.47m
MNKMallinckrodt Plc
-1.26%21.1018.5%$120.96m
SAGESAGE Therapeutics, Inc.
2.38%97.7110.9%$115.27m
JAZZJazz Pharmaceuticals Plc
0.48%138.702.2%$76.83m
ENDPEndo International Plc
-1.18%7.548.9%$66.95m
PCRXPacira Pharmaceuticals, Inc.
3.26%45.9510.7%$50.79m
ICPTIntercept Pharmaceuticals, Inc.
1.54%63.2022.0%$47.20m
ADMSAdamas Pharmaceuticals, Inc.
0.27%33.6816.9%$42.86m
UTHRUnited Therapeutics Corporation
-0.32%125.0114.5%$42.66m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.40%128.157.6%$39.70m
ICLRICON Plc
-1.09%117.064.1%$37.28m
MDCOMedicines Company
-1.47%30.9422.1%$36.25m
CTLTCatalent Inc
1.48%39.502.6%$33.34m

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.